Leaderboard

En | De
Sie sind hier: Onkologie » Gynäkologische Tumoren 27. Februar 2026
Suchen
medline.ch
Gynäkologische Tumoren
Erweiterte Suche
Dermatologie
Endokrinologie
Ernährung
Gastroenterologie
Gynäkologie
Hämatologie
Infektiologie
Kardiovaskuläre Erkrankungen
Muskuloskelettale Erkrankungen
Neurologie
Onkologie
Bewegungsapparat
Blut
Endokrine Organe
Gynäkologische Tumoren
Haut
Magen-Darm
ORL
Respirationstrakt
Urologische Tumoren
ZNS
Ophthalmologie
ORL
Pädiatrie
Psychiatrie
Respirationstrakt
Sportmedizin
Urologie-Nephrologie
Schrift: Schrift grösser Schrift kleiner

Rect Top
   Seite 1 von 16248  vorhergehende Seite nächste Seite
   
   Artikel 1 - 20 / 324955  
   
Timing matters: radiation necrosis risk of antibody-drug conjugates (ADCs) combined with radiation therapy in breast cancer brain metastases: a systematic review and comparative meta-analysis.
Neurosurg Rev
Zare A, Zare A, Kiani I, Delbari P, Mortezaei A, Ahmadvand MH, Rashidi F, Mohammadzadeh I, Azarmi E, Ghalehtaki R, Tafakhori A.
PMID: 41748827 [PubMed - in process]


CMAF-Net: cross-modal attention fusion with information-theoretic regularization for imbalanced breast cancer histopathology.
Sci Rep
Ativi WX, Chen W, Kwao L, Ayivi W, Sam F, Alqahtani A, Gu YH, Al-Antari MA.
PMID: 41748602 [PubMed - as supplied by publisher]


No evidence for genotype-treatment interactions with breast cancer endocrine therapy adverse effects in UK Biobank.
NPJ Breast Cancer
Mokbel K, Weedon MN, Moye V, Ruth KS, Jackson L.
PMID: 41748588 [PubMed - as supplied by publisher]


Bayesian Indirect Comparison and Cost-Effectiveness of Sacituzumab Govitecan Versus Sacituzumab Tirumotecan in Metastatic Triple-Negative Breast Cancer.
Value Health
Shu Y, Tang Y, Ding Y, Zhang W, Zhang Q.
PMID: 41747823 [PubMed - as supplied by publisher]


Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial.
ESMO Open
Paracchini L, Velle A, Di Gennaro P, Mannarino L, Ancona L, Lorusso D, Cecere SC, Colombo N, Beltrame L, Fagotti A, Tasca G, Piemontese M, Arenare L, Califano D, Galdiero F, Zadro R, Chiodini P, Perrone F, Biagioli E, D'Incalci M, Romualdi C, Pignata S, Marchini S.
PMID: 41747586 [PubMed - as supplied by publisher]


Potential of IMNN-001 in epithelial ovarian cancer: assessment of clinical findings.
Expert Opin Investig Drugs
Thaker PH, Lindborg SR, Limon A, Faller DV, Bradley WH, Anwer K, Alvarez RD.
PMID: 41746995 [PubMed - as supplied by publisher]


Effect of a supervised intermittent exercise program on insomnia in breast cancer patients undergoing chemotherapy.
Breast Cancer Res Treat
Drozd C, Curtit E, Jacquinot Q, Roux P, Paget-Bailly S, Gillet V, Meneveau N, Mougin F.
PMID: 41746533 [PubMed - in process]


Spatial Patterns of Breast Cancer Risk Associated with Industrial and Environmental Pollutants: A Scoping Review.
Toxics
Nahal D, Hoffpauir A, Kinariwala K, Tetteh P, Orenge F, Patel A, Ghalib A, Northeim K.
PMID: 41745813 [PubMed]


Dynamic Contrast-Enhanced MRI Kinetic Curve-Driven Parametric Radiomics for Predicting Breast Cancer Molecular Subtypes: A Multicenter and Interpretable Study.
Tomography
Wang T, Gong J, Wang S, Sun S, Zhou J, Lin L, Zhang D, You C, Gu Y.
PMID: 41745704 [PubMed - in process]


Reproductive Toxicity of Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer: A Case Report with a Literature Review.
Diseases
Tanase-Damian C, Antone NZ, Paun DL, Tanase I, Achima.
PMID: 41745089 [PubMed]


Metabolic Vulnerabilities as a Therapeutic Target in Breast Cancer.
Curr Oncol
Guo S, Addison CL.
PMID: 41744893 [PubMed - in process]


Estrogen Receptor-Low Positive (ER-Low) Breast Cancer: A Unique Clinical and Pathological Entity.
Curr Oncol
Faa G, Lai E, Ziranu P, Pretta A, Tiwari E, Dessì M, Solinas C, Saba G, Loi F, Codipietro C, Graziano S, Ottelio L, Dessena M, Coghe F, Suri JS, Saba L, Scartozzi M.
PMID: 41744886 [PubMed - in process]


Romanian Consensus Statement for Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer (HR+/HER2- mBC) and Triple-Negative Metastatic Breast Cancer (mTNBC).
Curr Oncol
Median MD, Antone NZ, Volov, Mazilu L, Negru , Curc, Ni, P, Ungureanu A, Lupu V, Oprean CM.
PMID: 41744884 [PubMed - in process]


Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Early Breast Cancer 2025.
Curr Oncol
Sehdev S, Joy AA, Boileau JF, Bouganim N, Brezden-Masley C, Cao JQ, Cescon DW, Chia S, Edwards S, Gelmon KA, Jerzak KJ, Kumar A, Laing K, LeVasseur N, Simmons C, Webster M, Manna M, On Behalf Of Patient Advocacy Breast Cancer Canada.
PMID: 41744876 [PubMed - in process]


Understanding Patients' Preferences for Discussing Sexuality After Surgery-A Qualitative Study of Sexuality and Body Image in Women with Ovarian Cancer.
Curr Oncol
Stöckl JR, Lee MM, Sehouli J, Pirmorady-Sehouli A.
PMID: 41744874 [PubMed - in process]


Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Metastatic Breast Cancer 2025.
Curr Oncol
Jerzak KJ, Kumar A, Boileau JF, Bouganim N, Brezden-Masley C, Cao JQ, Cescon DW, Chia S, Edwards S, Joy AA, Laing K, LeVasseur N, Lupichuk S, Sehdev S, Simmons C, Webster M, Gelmon KA, Manna M, On Behalf Of Patient Advocacy Breast Cancer Canada.
PMID: 41744870 [PubMed - in process]


Trop2-Based Antibody-Drug Conjugates: Emerging Strategy and Progress in Triple-Negative Breast Cancer Therapy.
Curr Oncol
Li T, Zhang T, Dang Y, Lin Y, Li X, Ling X.
PMID: 41744856 [PubMed - in process]


DUSP1: Triple-Negative Breast Cancer and Therapeutic Potential.
Curr Oncol
Niture S, Thotala D, Jaboin J, Seneviratne D.
PMID: 41744846 [PubMed - in process]


Real-World Utilization of Palbociclib as First-Line Treatment for Canadian HR+/HER2- Women with Metastatic Breast Cancer: Results from PALCAN Study.
Curr Oncol
Rayson D, Bertin J, Lemelin M, Tong M, Ng R, Ding P, Cheung WY, Sharma A, On PV, Feugère G, Lupichuk S.
PMID: 41744845 [PubMed - in process]


High-Risk Benign Breast Lesions: An Ontario Health (Cancer Care Ontario) Recommendations Report.
Curr Oncol
Eisen A, Bane A, Causer P, Cordeiro E, Fienberg S, Kornecki A, Kulkarni A, Hong NL, Mancuso T, Muradali D, Nofech-Mozes S, Roberts A, Shaheen R, Courtney S, Grove R, Brackstone M.
PMID: 41744831 [PubMed - in process]


   
   Artikel 1 - 20 / 324955    Seite 1 von 16248  vorhergehende Seite nächste Seite

 
Rect Bottom
Adserver Footer
 

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

 

Übersetzungsproblem?

mehr >>

  Zeitfenster  
   

Sky right 1